Skip to main content

ARCH Venture Partners — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

236
Companies
$22.6B
Total invested
$122.9M
Avg. check
22
Industries
Biotechnology 21Health Care 14Medical 10Life Science 8Pharmaceutical 7Biopharma 6+16 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 236
Magnet Biomedicine
September 2023

Magnet Biomedicine is a biotechnology research platform specializing in discovering true molecular glues.

Biotechnology · Cambridge$50.0M Series A
ROME Therapeutics
September 2023

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.

Biotechnology · Cambridge$72.0M Series B
OncoResponse
May 2023

OncoResponse is an immuno-oncology biotech company developing cancer immunotherapies leveraging human immune system responses.

Biopharma · Seattle$14.0M Series D
Recuro Health
April 2023

Recuro Health offers a holistic suite of virtual care services and supplemental benefits.

Health Care · Richardson$47.0M Series B
bit.bio
January 2026

Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development.

Biotechnology · Cambridge$50.0M Series C
Vizgen
January 2026

Vizgen provides spatial multi-omics platforms enabling researchers to reveal cellular insights through spatial transcriptomics proteomics.

Biotechnology · Cambridge$48.0M Series E
Just - Evotec Biologics
January 2026

Designing innovative technologies focused on accelerating global access to biotherapeutics.

Biopharma · SeattleGrant
Moonwalk Biosciences
January 2024

Moonwalk Biosciences operates a genomic medicine company that aims to provide a new class of precision epigenetic medications.

Artificial Intelligence (AI) · San Francisco$57.0M Series A
HI-Bio
January 2024

Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases.

Biotechnology · South San Francisco$95.0M Series B
Remix Therapeutics
January 2024

Remix Therapeutics is a biotechnology company that is working on developing small molecule medicines.

Biotechnology · Cambridge$60.0M Venture - Series Unknown
Paradigm
December 2025

Paradigm creates a platform that allow all patients to participate in clinical trials while also enhancing trial efficiency.

Health Care · New York$78.0M Series B
SciNeuro
December 2025

SciNeuro is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases.

Biopharma · Rockville$53.0M Venture - Series Unknown
Denali Therapeutics
December 2025

Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.

Biotechnology · San Francisco$200.0M Post-IPO Debt
Kura Oncology
January 2024

Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.

Biopharma · La Jolla$150.0M Post-IPO Equity
ONI
December 2021

ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers.

Biotechnology · Oxford$75.0M Series B
Syros Pharmaceuticals
December 2023

Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.

Biotechnology · Watertown$45.0M Post-IPO Equity
Protillion Biosciences
December 2022

Protillion Biosciences specializes in the design and development of protein-based drugs.

Biopharma · Burlingame$18.0M Series A
Generate Biomedicines
December 2024

Generate Biomedicines is a biotech company that combines biology, machine learning, and biological engineering to create biomedicines.

Artificial Intelligence (AI) · SomervilleSeries C
EQRx
December 2021

EQRx is a biotechnology company that focuses on re-engineering the process of drug discovery to make them affordable.

Biotechnology · Cambridge$1.2B Post-IPO Equity
Glympse Bio
December 2021

Glympse Bio is a biotechnology company that transforms disease detection and predict treatment response.

Biotechnology · Cambridge$18.0M Venture - Series Unknown
Erasca
January 2026

Erasca is a developer of oncology drugs intended to provide precision oncology options.

Biotechnology · San Diego$258.8M Post-IPO Equity
Aledade
December 2025

Aledade is a primary care center.

Health Care · Bethesda$500.0M Debt Financing
Carrick Therapeutics
December 2022

Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated.

Biotechnology · Boston$60.0M Series C
nChroma Bio
December 2024

nChroma Bio is a cutting-edge biotechnology business that is developing targeted in vivo delivery systems as well as best-in-class cargo.

Biotechnology · Boston$75.0M Venture - Series Unknown

Where ARCH Venture Partners invests

Biotechnology21
Health Care14
Medical10
Life Science8
Pharmaceutical7
Biopharma6

About ARCH Venture Partners's portfolio

How many companies has ARCH Venture Partners invested in?

ARCH Venture Partners has invested in 236 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does ARCH Venture Partners invest in?

ARCH Venture Partners's top investment sectors include Biotechnology, Health Care, Medical, Life Science, Pharmaceutical. The firm invests across 22 different industry categories.

What is ARCH Venture Partners's largest investment?

Among tracked funding rounds, EQRx received $1.2B in a Post-IPO Equity round. ARCH Venture Partners's total known invested capital is $22.6B.

What is the average investment size for ARCH Venture Partners?

ARCH Venture Partners's average investment size is $122.9M across its portfolio of 236 companies.

What are ARCH Venture Partners's most recent investments?

Recent ARCH Venture Partners portfolio additions include Magnet Biomedicine, ROME Therapeutics, OncoResponse, Recuro Health, bit.bio. These companies were founded in 2020 or later.

Reach the founders behind these 236 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →